Today: 21 May 2026
Rigetti stock slides as quantum-computing trade cools into year-end

Rigetti stock slides as quantum-computing trade cools into year-end

NEW YORK, December 29, 2025, 11:49 ET — Regular session

  • Rigetti shares fell about 3% in morning trade as quantum-computing stocks stayed volatile into year-end.
  • Recent swings in the group have been driven by profit-taking, thin holiday volumes and valuation concerns, Investors Business Daily reported.
  • Traders are watching for updates tied to Rigetti’s late-2025 technology milestone and the next earnings timeline.

Rigetti Computing’s shares fell about 3% on Monday, extending a late-December pullback in quantum-computing stocks as traders booked gains and waited for fresh catalysts.

The moves matter now because the quantum group has become a momentum trade into year-end, where lighter holiday liquidity can magnify swings in high-volatility names. Investors Business Daily said the sector’s recent slide followed a brief pop earlier this month that arrived “without major news,” and was later met by profit-taking and valuation jitters. Investors.com

Rigetti has drawn attention alongside peers such as IonQ and D-Wave, but much of the day-to-day trading has been driven by shifting sentiment toward the whole theme rather than a single company headline. Investors have been reassessing how quickly early-stage quantum companies can turn research progress into repeatable revenue.

Rigetti (RGTI.O) was down $0.66 at $21.72, after trading between $22.55 and $21.54. About 14.6 million shares had changed hands by late morning.

IonQ (IONQ.N) was down about 1.4% and Quantum Computing Inc (QUBT.O) was down about 2.6%, while D-Wave Quantum (QBTS.N) was up roughly 0.5%.

Quantum computers use “qubits” — the quantum version of a bit — which can in theory tackle certain problems faster than classical machines. For now, most pure-play quantum firms generate uneven revenue and rely heavily on R&D spending, which can leave their stocks sensitive to shifts in risk appetite. Investors.com

Rigetti’s most recent detailed update came with its third-quarter results filing in November, when it reported $1.9 million in revenue and an operating loss of $20.5 million for the quarter. The company said cash, cash equivalents and available-for-sale investments totaled $558.9 million as of Sept. 30, and about $600 million as of Nov. 6, helped by warrant exercises.

Investors have also been focused on whether Rigetti can deliver on near-term performance targets. “We remain on track to deliver our 100+ qubit chiplet-based quantum system … by the end of 2025,” Chief Executive Subodh Kulkarni said in the earnings release. SEC

Two-qubit gate fidelity — a common benchmark in quantum computing — measures how accurately the machine performs operations involving two qubits, with higher percentages indicating fewer errors. Rigetti has said it expects 99.5% median two-qubit gate fidelity for its 100+ qubit system.

In the same release, the company laid out targets for a 150+ qubit system by around the end of 2026 with 99.7% median two-qubit gate fidelity, and a 1,000+ qubit system by around the end of 2027 with 99.8% median two-qubit gate fidelity.

On the commercial side, Rigetti has pointed to purchase orders totaling about $5.7 million for two 9-qubit Novera systems, with delivery expected in the first half of 2026. The company has also highlighted government-backed work, including a $5.8 million Air Force Research Laboratory contract with QphoX, as it looks to build out networking capabilities for superconducting quantum systems.

Traders are watching whether the stock stabilizes after hitting $21.54 at its session low, and whether the group gets any new catalyst beyond year-end repositioning. The next major scheduled check-in is earnings: Zacks expects Rigetti’s next report around March 4, 2026, though the company has not announced a date.

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
New expressway makes Ahmedabad-to-Salangpur Hanuman temple trip faster — even before official opening
Previous Story

New expressway makes Ahmedabad-to-Salangpur Hanuman temple trip faster — even before official opening

Caterpillar stock slips in thin year-end trade as CEO discloses Form 4 award
Next Story

Caterpillar stock slips in thin year-end trade as CEO discloses Form 4 award

Go toTop